ПРОДОЛЖИТЕЛЬНОСТЬ ДВОЙНОЙ АНТИТРОМБОЦИТАРНОЙ ТЕРАПИИ. ФАКТЫ И ПРЕДПОЛОЖЕНИЯ
https://doi.org/10.15829/1560-4071-2016-2-75-83
Аннотация
В обзорной статье представлены современные данные, касающиеся одного из ключевых вопросов современной кардиологии — продолжительности двойной антитромбоцитарной терапии (ДАТТ) у пациентов с различными формами ишемической болезни сердца. Проведен анализ актуальных клинических рекомендаций, касающихся этого вопроса, освещены результаты недавних клинических исследований и проведенных мета-анализов. На основании результатов международных исследований постулируется необходимость тщательной оценки пользы и риска как пролонгирования, так и укорочения ДАТТ и представляются возможные показания для таких изменений сроков 12-месячной ДАТТ.
Об авторах
О. Л. Барбараш
ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-
сосудистых заболеваний;
ГБОУ ВПО Кемеровская государственная медицинская академия Минздрава России
Россия
Россия
д.м.н., профессор, директор, зав. кафедрой кардиологии и сердечно-сосудистой хирургии,
Кемерово
В. В. Кашталап
ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-
сосудистых заболеваний;
ГБОУ ВПО Кемеровская государственная медицинская академия Минздрава России
Россия
Конфликт интересов: Авторы статьи не заявляют о конфликте интересов
Россия
д.м.н., зав. лабораторией патофизиологии мультифокального атеросклероза, доцент кафедры кардиологии и сердечно-сосудистой хирургии,
Кемерово
Конфликт интересов: Авторы статьи не заявляют о конфликте интересов
Список литературы
1. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 47: 1982-8.
2. Sabouret P, Rushton-Smith SK, Kerneis M, et al. Dual antiplatelet therapy: optimal timing, management, and duration. Eur Heart J – Cardiovascular Pharmacotherapy 2015; 1: 198-204.
3. Montalescot G, Brieger D, Dalby A, et al. Duration of Dual Antiplatelet Therapy after Coronary Stenting. J Am Coll Cardiol 2015; 66(7): 832-47.
4. 2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) European Heart Journal Advance Access published August 29, 2014. European Heart Journal doi:10.1093/eurheartj/ehu278.
5. Сutlip DE, Kereiakes DJ, Mauri L, et al. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. J Am Coll Cardiol Interv 2015; 8: 404-10.
6. Maury L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Eng J Med 2007; 356: 1020-9.
7. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64 (24): e139-228.
8. 2011 ACCF/AHA/SCAI Guideline for Percutaneus Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124: 574-651.
9. The Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
10. Yusuf S, Mehta SR, Zhao F, et al. For the CURE Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003; 107: 966-72.
11. Steinhubl SR, Berger PB, Mann JT.3rd, et al. For CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.
12. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
13. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999-1010.
14. Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal 2014; 35: 2083-93.
15. Campo G, Tebaldi M, Vranckx P, et al. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). J Am Coll Cardiol 2014; 63: 506-12.
16. Gwon HC, Hahn J, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012; 125: 505-13.
17. Giustino G, Baber U, Sartori S, et al. Duration of dual antiplatelet therapy after drug-eluting stent impantation. J Am Coll Cardiol 2015; 65(13): 1298-310.
18. Price MJ. The optimal duration of dual antiplatelet therapy after drug-eluting stent implantation. Am Coll Cardiol 2015; 65(13): 1311-3.
19. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of long-term perspective. European Heart Journal. doi: 10.1093/eurheartj/ehu505.
20. Barbarash OL, Karetnikova VN, Kashtalap VV The patient after myocardial infarction: how to reduce a risk of recurrent ischemic event? Cardiosomatics 2015; 6(2): 12-9. Russian (Барбараш О.Л., Каретникова В.Н., Кашталап В.В. Пациент после инфаркта миокарда: как снизить риск повторного ишемического события? Кардиосоматика 2015; 6 (2): 12-9).
21. Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non–Q-wave myocardial infarction: a myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy. Circulation 2002; 106: 1690-5.
22. Cannon CP, Braunwald E, McCabe CH, et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 2004; 350 (15): 1495-504.
23. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-66.
24. Yeh RW, Kereiakes DJ, Steg PG, et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. JACC 2015; 65(20): 2211-21.
25. Bonaca MP, Bhatt D, Braunwald E, et al. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014; 167: 437-44.e5.
26. Bonaca MP, Bhatt D, Cohen M, et al. for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015. doi: 10.1056/NEJMoa1500857.
27. Ubell JA, Bonaca MC, Collet JP, et al. Long-term antiplatelaet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart Journal 2015. doi: 10.1093/eurheartj/ehv443.
28. Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382: 614-23.
29. Urbano-Moral JA, Lopez-Haldon JE, Fernandez M, et al. Prognostic value of different serum biomarkers for left ventricular remodeling after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart 2012; 98: 1153-9.
30. Barbarash OL, Zykov MV, Kashtalap VV, et al. Prognostic value of different inflammatory markers in STEMI. Kardiologiia 2011; 3: 24-30. Russian (Барбараш О.Л., Зыков М.В., Кашталап В.В., Осокина А.В., Бернс С.А., Каретникова В.Н., Барбараш Л.С. Прогностическая ценность различных маркеров воспаления при инфаркте миокарда с подъемом сегмента ST. Кардиология. 2011; 3: 24-30).
31. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal Advance Access published August 29, 2015. European Heart Journal. doi:10.1093/eurheartj/ehv320.
32. Matteau A, Yeh RW, Camenzind E, et al. Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents Am J Cardiol. 2015; 116(5): 686-93. doi: 10.1016/j.amjcard.2015.05.036. Epub 2015 Jun 3.
33. The SPS3 Investigators. Effect of clopidogrel added to aspirin in patients with recent lacunar stroke. N Eng J Med 2012; 367: 817-25.
34. Elmariah S, Mauri L, Doros G, et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet 2015; 385: 792-8.
35. Spoon DB, Psaltis PJ, Singh M, et al. Trends in Cause of Death after percutaneous coronary intervention. Circulation 2014; 129: 1286-94.
36. Boytsov SA Prevention of noncommunicable diseases in the country: from what to do to how to do. Preventive Medicine 2012; 2: 3-10. Russian (Бойцов С.А. Профилактика неинфекционных заболеваний в стране: от «что делать» к «как делать». Профилактическая медицина 2012; 2: 3-10).
37. Erlikh AD. Dual antiplatelet therapy: needs for compliance to therapy and possibilities its increase. Atherothrombosis 2014; 2: 25-33. Russian (Эрлих А.Д. Двойная антитромбоцитарная терапия: необходимость приверженности к лечению и возможности ее повышения. Атеротромбоз 2014; 2: 25-33).
38. Tolpygina SN, Polyanskaya YuN, Martsevich SYu Treatment of patients with chronic ischemic heart disease in real clinical practice according to the data from PROGNOZ IBS register (part 2). Ration Pharmacother Cardiol 2013; 9(5): 494-9. Russian (Толпыгина С.Н., Полянская Ю.Н., Марцевич С.Ю. Лечение пациентов с хронической ИБС в реальной клинической практике по данным регистра ПРОГНОЗ ИБС (часть 2). Рациональная фармакотерапия в кардиологии 2013; 9(5): 494-9).
39. Abu-Assi E, Raposeiras-Roubin S, Garcia-Acuna JM, et al. Bleeding risk stratification in an era of aggressive management of acute coronary syndromes. World J Cardiol 2014; 6(11): 1140-48.
40. Garrat KN, Weaver WD, Jenkins RG, et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberte paclitaxel-eluting coronary stent placement. Circulation 2015; 131: 62-73.
41. Cayla G, Guisset T, Silvan J, et al. Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndromes design of the randomized antarctic study. Am Heart J 2014; 168: 674-81.
42. Sabouret P, Rushton-Smith SK, Kerneis M, et al. Dual antiplatelet therapy: optimal timing, management, and duration. Eur Heart J – Cardiovascular Pharmacorherapy 2015; 1: 198-204.
43. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59: 2159-64.
44. Collet JP, Cuisset T, Range G et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Eng J Med 2012; 367: 2100-9.
45. Rossello X, Pocock SJ, Julian DG Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. J Am Coll Cardiol 2015; 66(11): 1273-85. doi: 10.1016 /j.jacc.2015.07.018.
Рецензия
Для цитирования:
Барбараш О.Л., Кашталап В.В. ПРОДОЛЖИТЕЛЬНОСТЬ ДВОЙНОЙ АНТИТРОМБОЦИТАРНОЙ ТЕРАПИИ. ФАКТЫ И ПРЕДПОЛОЖЕНИЯ. Российский кардиологический журнал. 2016;(2):75-83. https://doi.org/10.15829/1560-4071-2016-2-75-83
For citation:
Barbarash O.L., Kashtalap V.V. TIMELINE FOR THE DOUBLE ANTIPLATELET THERAPY. FACTS AND SUGGESTIONS. Russian Journal of Cardiology. 2016;(2):75-83. (In Russ.) https://doi.org/10.15829/1560-4071-2016-2-75-83
Просмотров:
805
Послать статью по эл. почте 